Table 1.
Patient demographic lesion characteristics and lesion locations.
Fig 1.
A post-operative case of high-grade glioma showing recurrent tumor with foci of susceptibility in the mural nodule as well as blood fluid level in the cystic component (E, open arrow).
The mural nodule is showing high CBV on T1- perfusion (E, thick arrow). The corresponding area shows relatively low CBV on T2* perfusion MRI. Another foci with increased CBV seen posteriorly detected well on both T2*- and T1- perfusion MRI (E and F, thin arrows). Artifactual increased CBV is seen within the cystic component of the tumor on T2*- perfusion (F, thin arrow).
Fig 2.
Gliomas are showing abundant susceptibility on gradient imaging: T1- perfusion showing the peripheral area of the increase rCBV (arrow).
T1- perfusion also shows the scattered area of increase perfusion. On T2*-perfusion subtle increase in rCBV noted, and artificially high rCBV perfusion was seen in the part of tumor showing susceptibility.
Table 2.
Summary of T1- and T2*-perfusion derived rCBV values discriminating grade—III (n = 31) and grade -IV (n = 12) astrocytic brain tumors.
Fig 3.
Scatterplot of rCBV values derived from T1- and T2*-perfusion MRI data demonstrating the distribution of the rCBV values recorded by these two methods.
Fig 4.
Bland-Altman is demonstrating the limits of agreements between two independent observers recorded the rCBV values from T2*- and T1- perfusion MRI data.
The midline represents the mean values for the data points, and the top and bottom line represents the 1.96 and -1.96 limits of agreements, respectively.
Fig 5.
Bland-Altman is demonstrating the limits of agreements between the rCBV values recorded from two methods (T2*- and T1- perfusion MRI).
The midline represents the mean values for the data points, and the top and bottom line represents the 1.96 and -1.96 limits of agreements, respectively.
Fig 6.
The Receiver operating characteristic (ROC) curves for the rCBV values derived from T1- and T2*-perfusion.